InflaRx (IFRX) Cash & Equivalents Growth (3y) (2019 - 2026)
InflaRx (IFRX) Cash & Equivalents Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -23.18% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 14.34% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.45% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.22% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.85% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -27.97% |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.30% |
| Dec 31, 2025 | 3.97% |
| Sep 30, 2025 | -25.36% |
| Jun 30, 2025 | -3.64% |
| Mar 31, 2025 | 3.39% |
| Dec 31, 2024 | -13.16% |
| Sep 30, 2024 | -29.61% |
| Jun 30, 2024 | -38.14% |
| Mar 31, 2024 | -34.03% |
| Dec 31, 2023 | -23.73% |
| Sep 30, 2023 | -23.31% |
| Jun 30, 2023 | -19.07% |
| Mar 31, 2023 | -54.10% |
| Dec 31, 2022 | -23.23% |
| Sep 30, 2022 | -15.51% |
| Jun 30, 2022 | -35.30% |
| Mar 31, 2022 | -5.67% |
| Dec 31, 2021 | -21.97% |
| Sep 30, 2021 | 7.98% |
| Jun 30, 2021 | -22.37% |